The Technion’s story has been intertwined with Israel’s for more than a century, from laying the foundations for a new nation to shaping its future.
From medicine to security, explore how the Technion is advancing Israel and improving lives around the world.
View All Impact Areas
Explore stories, news, insights, and data across articles, videos, and podcasts.
view all content types
among universities worldwide for producing undergrad entrepreneurs
countries
of the student body are Arab Israeli
The Technion’s story has been intertwined with Israel’s for more than a century, from laying the foundations for a new nation to shaping its future.
Explore ATS, the Technion, and the people behind the breakthroughs redefining what's possible for Israel and the world.
Learn More About ATSATS is a community of supporters, innovators, and champions of possibility united by one mission: transforming Israel and the world through science and discovery.
Learn MoreFor more than 100 years, the Technion has been Israel's technological engine and leading driver of innovation, technology, and entrepreneurship, transforming ideas into impact.
Learn More
Step inside Israeli innovation at the David and Janet Polak Visitors Center. Experience our 360° immersive movie and tech exhibition. Open to individuals and groups.
Learn MoreFrom medicine to security, explore how the Technion is advancing Israel and improving lives around the world.
View All Impact AreasExplore stories, news, insights, and data across articles, videos, and podcasts.
view all content typesExplore ATS, the Technion, and the people behind the breakthroughs redefining what's possible for Israel and the world.
Learn More About ATS
The technology, based on the Nano-Ghosts platform, makes it possible to reduce the drug dose a million-fold without reducing its efficacy.
Researchers in the Faculty of Biotechnology and Food Engineering at the Technion developed a technology that inhibits development of melanoma using one-millionth of the active ingredient. The study, published in Advanced Functional Materials, was led by Professor Marcelle Machluf, dean of the faculty, and Ph.D. student Lior Levy.
This development is a significant breakthrough in the field of immunotherapy — an innovative medical approach that uses the body’s own immune system to destroy cancer cells. Immunotherapy can destroy cancer cells more accurately and specifically than synthetic anti-cancer drugs. But since malignant tumors are heterogeneous and evasive, they can sometimes fool the immune system.
At the core of Prof. Machluf’s new development is a protein called TRAIL, which exists in the body’s immune system and knows how to induce apoptosis (programmed cell death) in cancer cells. TRAIL is selective, affecting only cancerous cells — not other healthy cells in the body. While TRAIL can help the body spot evasive cancer cells, TRAIL proteins don’t survive in the body for very long — until now.
Nano-Ghosts for Cancer Care
Prof. Machluf’s highly inventive nano-ghosts technology empties specific biological cells (mesenchymal stem cells) in a way that leaves only the cell membrane and reduces their size to a nanometer scale. Any drug can be inserted into the membrane and injected directly into the bloodstream. Because the body’s immune system treats nano-ghosts as natural cells, it delivers them to the affected site. They do not release the drug on the way, and therefore do not harm healthy tissue.

A schematic description of preparing Nano-Ghosts from cells that underwent genetic or metabolic manipulation and now carry the TRAIL protein. These cells, with Nano-Ghost targeting for cancer and with the TRAIL protein, can reach the cancer site and fight effectively while using one millionth the concentration of the active ingredient required without this system.
By using nano-ghosts to deliver TRAIL proteins to cancerous cells, Prof. Machluf is able to turn her nano-ghost technology from a “taxi” that delivers drugs to a target into a “tank” in the war against cancer. The innovative platform delivers the drug to the tumor, successfully treating the tumor while using just one millionth of the concentration of the drug dosage required without this system.
While Prof. Machluf demonstrated the success of nano-ghosts in treating melanoma, she is optimistic nano-ghosts could be deployed to fight many other types of cancer.
December 02, 2021
New technology, based on the Nano-Ghosts platform, makes it possible to reduce cancer drug dose a million-fold without reducing its efficacy.
3 mins
X (opens in a new tab) / Facebook (opens in a new tab) / LinkedIn (opens in a new tab) / Email / Copy Link
Cancer / Faculty / Nanotechnology /
Could a mistake actually be the start of something great? In this surprising talk, Prof. Hemi Rotenberg shares the story of a “scientific screwup” that changed everything. What started as a mishap in the lab led his team to discover a revolutionary optoelectronic material that can now pace hearts and modulate nerves using nothing but […]
Alzheimer’s disease is one of the greatest medical and societal challenges of our time. The progressive brain disorder now affects millions of families worldwide, and the number of cases is expected to rise as populations age. At the Technion, groundbreaking research is challenging conventional thinking about the disease and opening new avenues that could lead […]
Why do so many life-saving technologies never make it out of the lab? Prof. Marcelle Machluf demonstrates how combining scientific rigor with business vision is the only way to bring practical solutions to the patients who need them most. As a case in point, she shares her personal transformation from researcher to entrepreneur. This talk […]
Stay on top of the latest breaking scientific discoveries from Israel and the Technion. Subscribe to the ATS newsletter.